JP2019501151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501151A5 JP2019501151A5 JP2018529176A JP2018529176A JP2019501151A5 JP 2019501151 A5 JP2019501151 A5 JP 2019501151A5 JP 2018529176 A JP2018529176 A JP 2018529176A JP 2018529176 A JP2018529176 A JP 2018529176A JP 2019501151 A5 JP2019501151 A5 JP 2019501151A5
- Authority
- JP
- Japan
- Prior art keywords
- molar ratio
- antibody
- motomeko
- composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188988A JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201600702 | 2016-11-10 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600702 | 2016-11-10 | ||
| PCT/EP2016/079517 WO2017093447A1 (en) | 2015-12-01 | 2016-12-01 | Anti-death receptor antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188988A Division JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501151A JP2019501151A (ja) | 2019-01-17 |
| JP2019501151A5 true JP2019501151A5 (enExample) | 2020-01-16 |
Family
ID=58796495
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529087A Active JP7254515B2 (ja) | 2015-12-01 | 2016-12-01 | 抗ｄｒ５抗体およびその使用方法 |
| JP2018529176A Withdrawn JP2019501151A (ja) | 2015-12-01 | 2016-12-01 | 抗デスレセプター抗体およびその使用方法 |
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529087A Active JP7254515B2 (ja) | 2015-12-01 | 2016-12-01 | 抗ｄｒ５抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190144554A1 (enExample) |
| EP (4) | EP4464333A3 (enExample) |
| JP (3) | JP7254515B2 (enExample) |
| KR (1) | KR20180098567A (enExample) |
| CN (2) | CN109476737A (enExample) |
| AU (2) | AU2016363770A1 (enExample) |
| BR (2) | BR112018011100A2 (enExample) |
| CA (2) | CA3007031A1 (enExample) |
| IL (1) | IL259713B1 (enExample) |
| MA (1) | MA43365A (enExample) |
| MX (1) | MX2018006333A (enExample) |
| SG (1) | SG11201803956UA (enExample) |
| UA (1) | UA126897C2 (enExample) |
| WO (2) | WO2017093448A1 (enExample) |
| ZA (1) | ZA201803079B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3960855A1 (en) * | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| WO2017093448A1 (en) | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
| MX2019014407A (es) * | 2017-06-07 | 2020-02-05 | Genmab Bv | Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados. |
| WO2019025545A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE |
| EP3710482A4 (en) | 2017-11-14 | 2021-08-18 | University Of Virginia Patent Foundation | COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES |
| CN109957020A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| JP2021510740A (ja) * | 2018-01-24 | 2021-04-30 | ゲンマブ ビー．ブイ． | ポリペプチド変種およびそれらの用途 |
| EP3788074A1 (en) | 2018-05-03 | 2021-03-10 | Genmab B.V. | Antibody variant combinations and uses thereof |
| CN120865412A (zh) * | 2018-07-13 | 2025-10-31 | 根马布股份公司 | Cd38抗体变体及其用途 |
| CN112638946A (zh) | 2018-08-16 | 2021-04-09 | 坎塔吉亚有限责任公司 | 抗il1rap抗体组合物 |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| US20220411529A1 (en) | 2019-11-06 | 2022-12-29 | Genmab B.V. | Antibody variant combinations and uses thereof |
| MX2022014259A (es) * | 2020-05-12 | 2022-12-07 | Igm Biosciences Inc | Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer. |
| CN111778333B (zh) * | 2020-07-03 | 2022-11-18 | 东莞市滨海湾中心医院 | 测定edar表达水平的试剂的应用和试剂盒 |
| WO2022018294A1 (en) | 2020-07-23 | 2022-01-27 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| US20230391881A1 (en) * | 2020-10-14 | 2023-12-07 | University Of Virginia Patent Foundation | Compositions and methods for overcoming dr5-induced immune evasion by solid tumors |
| CN112915211B (zh) * | 2021-02-07 | 2022-05-06 | 成都中医药大学 | 一种pd-l1靶向肽药物偶联物及其合成方法和应用 |
| US20250376532A1 (en) * | 2021-08-20 | 2025-12-11 | University Of Virginia Patent Foundation | Strategy for highly superior dr5 activation including in tumors and cancers |
| TW202509071A (zh) * | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| GB202315963D0 (en) * | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| WO2025160152A2 (en) * | 2024-01-23 | 2025-07-31 | The Regents Of The University Of California | Fas antibody and its use in treating cancers |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US835A (en) | 1838-07-12 | X i i i x | ||
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US761218A (en) | 1899-10-05 | 1904-05-31 | U S Standard Voting Machine Co | Register or counter. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0904366A1 (en) | 1996-04-01 | 1999-03-31 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| WO1998032856A1 (en) | 1997-01-28 | 1998-07-30 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| ATE411385T1 (de) | 1998-01-15 | 2008-10-15 | Genentech Inc | Apo-2 ligand |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| PT1192185E (pt) | 1999-06-09 | 2006-11-30 | Genentech Inc | Sinergismo de agonista do receptor de apo-2l e cpt-11 |
| US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US7115717B2 (en) | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| JP4309758B2 (ja) * | 2001-05-25 | 2009-08-05 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Ｔｒａｉｌレセプターに免疫特異的に結合する抗体 |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| CA2451680C (en) | 2001-07-03 | 2011-04-19 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| KR20040081422A (ko) | 2001-11-01 | 2004-09-21 | 유에이비 리서치 파운데이션 | 종양 괴사 인자-관련 세포사멸-유도 리간드 수용체에선택적인 항체와 다른 치료제와의 복합물 |
| US20040019915A1 (en) | 2002-04-01 | 2004-01-29 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
| PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| ES2426817T3 (es) * | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| CA2599734C (en) | 2005-03-03 | 2014-01-28 | Immunomedics, Inc. | Humanized l243 antibodies |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| TW200904072A (en) | 2007-07-05 | 2009-01-16 | Ic Plus Corp | System and method for generating interrupt |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| ES2524553T3 (es) | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US20120070432A1 (en) | 2009-05-28 | 2012-03-22 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| CN103339145A (zh) * | 2010-09-22 | 2013-10-02 | 安姆根有限公司 | 运载体免疫球蛋白及其用途 |
| WO2012057288A1 (ja) * | 2010-10-29 | 2012-05-03 | 第一三共株式会社 | 新規抗ｄｒ５抗体 |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| HRP20201004T1 (hr) | 2011-12-20 | 2020-10-16 | Medimmune, Llc | Modificirani polipeptidi za skelete bispecifičnog protutijela |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| PT2869845T (pt) | 2012-07-06 | 2019-12-09 | Genmab Bv | Proteína dimérica com mutações triplas |
| EP2684896A1 (en) * | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| KR20240123420A (ko) * | 2013-01-10 | 2024-08-13 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| WO2017093448A1 (en) | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
| WO2018083126A1 (en) | 2016-11-01 | 2018-05-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| KR20190115057A (ko) | 2017-02-10 | 2019-10-10 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
-
2016
- 2016-12-01 WO PCT/EP2016/079518 patent/WO2017093448A1/en not_active Ceased
- 2016-12-01 JP JP2018529087A patent/JP7254515B2/ja active Active
- 2016-12-01 BR BR112018011100-7A patent/BR112018011100A2/en active Search and Examination
- 2016-12-01 EP EP24170877.5A patent/EP4464333A3/en active Pending
- 2016-12-01 EP EP16805416.1A patent/EP3383905A1/en not_active Withdrawn
- 2016-12-01 US US15/780,268 patent/US20190144554A1/en not_active Abandoned
- 2016-12-01 MA MA043365A patent/MA43365A/fr unknown
- 2016-12-01 MX MX2018006333A patent/MX2018006333A/es unknown
- 2016-12-01 CN CN201680080715.XA patent/CN109476737A/zh active Pending
- 2016-12-01 CA CA3007031A patent/CA3007031A1/en active Pending
- 2016-12-01 CN CN201680069617.6A patent/CN108884158A/zh active Pending
- 2016-12-01 CA CA3007033A patent/CA3007033A1/en active Pending
- 2016-12-01 WO PCT/EP2016/079517 patent/WO2017093447A1/en not_active Ceased
- 2016-12-01 AU AU2016363770A patent/AU2016363770A1/en not_active Abandoned
- 2016-12-01 BR BR112018011058-2A patent/BR112018011058A2/en active Search and Examination
- 2016-12-01 EP EP24172544.9A patent/EP4467648A3/en active Pending
- 2016-12-01 UA UAA201807311A patent/UA126897C2/uk unknown
- 2016-12-01 JP JP2018529176A patent/JP2019501151A/ja not_active Withdrawn
- 2016-12-01 EP EP16805417.9A patent/EP3383906A1/en not_active Withdrawn
- 2016-12-01 US US15/780,285 patent/US20190202926A1/en not_active Abandoned
- 2016-12-01 KR KR1020187018606A patent/KR20180098567A/ko not_active Ceased
- 2016-12-01 SG SG11201803956UA patent/SG11201803956UA/en unknown
-
2018
- 2018-05-10 ZA ZA2018/03079A patent/ZA201803079B/en unknown
- 2018-05-30 IL IL259713A patent/IL259713B1/en unknown
-
2019
- 2019-06-25 US US16/451,714 patent/US10882913B2/en active Active
-
2020
- 2020-12-01 US US17/108,373 patent/US12247080B2/en active Active
-
2022
- 2022-03-01 US US17/684,238 patent/US20220411522A1/en active Pending
- 2022-11-28 JP JP2022188988A patent/JP7679347B2/ja active Active
-
2024
- 2024-01-15 AU AU2024200261A patent/AU2024200261A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501151A5 (enExample) | ||
| JP2019500869A5 (enExample) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| JP2020502046A5 (enExample) | ||
| JP2020522543A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2018503365A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| ES2992868T3 (en) | Combination of tim-4 antagonist and pd-1 antagonist and methods of use | |
| JP2017514795A5 (enExample) | ||
| RU2017105118A (ru) | Нейтрализация ингибирующих путей в лимфоцитах | |
| JP2018516966A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2016528195A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| RU2016101109A (ru) | Медицинское применение агонистов cd38 | |
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2015512412A5 (enExample) | ||
| CN110898226A (zh) | Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法 | |
| JP2019529416A5 (enExample) |